Efficacy and tolerability of combined antiretroviral treatment with bictegravir/emtricitabine/tenofovir alafenamide initiated at the time of primary HIV infection-Reference-Cited by-同舟云学术

Efficacy and tolerability of combined antiretroviral treatment with bictegravir/emtricitabine/tenofovir alafenamide initiated at the time of primary HIV infection

Published:2021-06-10 Issue:9 Volume:76 Page:2484-2485
ISSN:0305-7453
Container-title:Journal of Antimicrobial Chemotherapy
language:en
Short-container-title:

Author:

Bachelard A¹,Isernia V¹,Vallois D¹,Le Gac S¹,Chalal L¹,Landman R¹²,Damond F³,Descamps D²³,Yazdanpanah Y¹²,Peytavin G²⁴^ORCID,Ghosn J¹²

Affiliation:

1. AP-HP, Hospital Bichat—Claude-Bernard, Infectious and Tropical Diseases, Paris, France

2. IAME—UMR 1137 INSERM, Université de Paris, Paris, France

3. AP-HP, Hospital Bichat-Claude Bernard, Virology Laboratory, Paris, France

4. AP-HP, Hospital Bichat-Claude Bernard, Pharmacology-Toxicology Laboratory, Paris, France

Funder

internal funding

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)

Link

http://academic.oup.com/jac/article-pdf/76/9/2484/39711729/dkab192.pdf

Reference9 articles.

1. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society–USA panel;Günthard;JAMA,2016

2. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled noninferiority trial;Gallant;Lancet,2017

3. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial;Sax;Lancet,2017

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, Phase 3 trial;Journal of Antimicrobial Chemotherapy;2022-06-28